Compare Deutsche Bank AG (DB) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Deutsche Bank AG vs TG Therapeutics Inc — how do they compare? Deutsche Bank AG trades at $33.69 (market cap $62.42B), while TG Therapeutics Inc trades at $55.14 (market cap $8.16B). The key difference: Deutsche Bank AG is far larger — about 7.6× TG Therapeutics Inc's market cap, and Deutsche Bank AG pays a 3.46% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Deutsche Bank AG for 80 Days and TG Therapeutics Inc for 16 Days on average.
| DB | TGTX | |
|---|---|---|
Market Cap | $62.42B | $8.16B |
Volume | 2,918,760 | 1,735,121 |
Sector | Financials | Health |
52-Week High | $41.56 | $59.06 |
52-Week Low | $28.37 | $26.94 |
Typical Hold Time | 80 Days | 16 Days |
Enterprise Value | $77.06B | $8.37B |
Dividend Yield | 3.46% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Deutsche Bank (DB) trades at $33.68, up 0.39% today, with a bearish technical signal from moving averages but recent earnings beats. The stock shows attractive valuation with a P/E of 9.09 and P/B of 0.71, while net income surged to $6.93B in 2025. News highlights include strategic appointments and a raised 2026 net interest income outlook, though Q3 investment banking revenue is expected to be flat to slightly down.
The outlook is mixed: strong fundamentals and cost-saving initiatives support growth toward 2028 targets, but bearish technicals and a high proportion of hold ratings suggest near-term caution. Key risks include volatile investment banking revenue and macroeconomic pressures, while institutional sentiment remains divided with 57.58% hold ratings.
TG Therapeutics (TGTX) trades at $54.80, up 3.49% today, but faces a bearish technical signal with recent earnings misses. Revenue growth is strong, with 2026 guidance raised to $950M for BRIUMVI, and net income margins exceed 55%. However, cash flow was negative in 2025, and a shareholder litigation investigation adds near-term uncertainty.
The outlook is mixed: analyst consensus is bullish with an $80.50 price target, but execution risks and earnings volatility persist. Upside hinges on BRIUMVI market share gains and subcutaneous formulation progress, while legal and competitive pressures pose threats to shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Deutsche Bank AG
In July 2019, Deutsche Bank announced another restructuring plan hoping to revitalize revenue, reduce costs, and return to profitability. The largest moving pieces of the new plan is the full exit of global equity sales & trading, the scaling back of its fixed income business, as well as 18,000 FTE reductions until 2022. The remaining core business segments include private banking, corporate banking, asset management, and investment banking.
Read more on DB →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
